EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3‐ d ]pyrimidine derivatives as EGFR inhibitors

Menna Tallah M Sayed, Peter A Halim, Afaf K El-Ansary, Rasha A Hassan iD

Drug Development Research · 2023-09 · 84 (6) · 1299-1319

DOI: 10.1002/ddr.22088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 25.06.2023. Verfasst von Menna Tallah M Sayed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Antineoplastic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New series of 20 thieno[2,3‐ d ]pyrimidine derivatives have been synthesized. The National Cancer Institute evaluated all the newly synthesized compounds for their antiproliferative activity against a panel of 60 cancer cell lines. Compound 7b exhibited a remarkable antineoplastic activity at 10 µM dose and was therefore tested at five dose concentrations. The significant and broad‐spectrum antineoplastic action of compound 7b was observed against 37 of the tested cancer cell lines with a dose that inhibits 50% of the growth compared to control values in the micromolar range of 1.95–9.6 µM. The dose which inhibits the growth completely in the cytostatic range of 3.99–100 µM was also observed. Compound 7b effectively inhibited epidermal growth factor receptor (EGFR) with 50% inhibition concentration value (IC 50 ) = 0.096 ± 0.004 compared to erlotinib with IC 50 = 0.037 ± 0.002. Moreover, compound 7b revealed a powerful downregulation effect on total EGFR concentration and its phosphorylation. In addition, compound 7b inhibited phosphatidylinositol 3‐kinase, protein kinase B, and the mammalian target of rapamycin pathway phosphorylation. Furthermore, compound 7b raised total apoptosis by 21.93‐fold in the ovarian cancer cell line (OVCAR‐4) and caused an arrest in the cell cycle in the G1/S phase. It also raised the level of caspase‐3 by 4.72‐fold. Furthermore, to determine the binding manner of the most effective derivatives and validate their capacity to comply with the pharmacophoric properties necessary for EGFR inhibition, they were docked into the active site of the EGFR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsAntineoplastic AgentsMolecular StructureStructure-Activity RelationshipCell ProliferationCell Line, TumorDrug Screening Assays, AntitumorPyrimidinesProtein Kinase InhibitorsMolecular Docking Simulation

Stichwörter der Autor:innen

EGFRanticancer activityapoptosiscaspase 3cell cyclemolecular dockingphosphorylated EGFRthieno[2,3-d]pyrimidine

Substanzen

ErbB ReceptorsAntineoplastic AgentsPyrimidinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

ORCID-Profile: Rasha A Hassan

Zitieren

APA

Sayed, M. T. M., Halim, P. A., El-Ansary, A. K., & Hassan, R. A. (2023). Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3‐ d ]pyrimidine derivatives as EGFR inhibitors. Drug Development Research, 84(6), 1299-1319. https://doi.org/10.1002/ddr.22088

Vancouver

Sayed MTM, Halim PA, El-Ansary AK, Hassan RA. Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3‐ d ]pyrimidine derivatives as EGFR inhibitors. Drug Development Research. 2023;84(6):1299-1319. doi:10.1002/ddr.22088

BibTeX
@article{Sayed2023,
  author = {Sayed, Menna Tallah M and Halim, Peter A and El-Ansary, Afaf K and Hassan, Rasha A},
  title = {Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3‐ d ]pyrimidine derivatives as EGFR inhibitors},
  journal = {Drug Development Research},
  year = {2023},
  volume = {84},
  number = {6},
  pages = {1299--1319},
  doi = {10.1002/ddr.22088}
}
Kostenlos starten →